Literature DB >> 23086695

Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma.

Hatim Husain1, Amanda Psyrri, Ana Markovic, Theodore Rampias, Eirini Pectasides, Hao Wang, Robbert Slebos, Wendell G Yarbrough, Barbara Burtness, Christine H Chung.   

Abstract

OBJECTIVES/HYPOTHESIS: Epidermal growth factor receptor (EGFR) and p16 (a surrogate marker of human papillomavirus [HPV] infection) expression are strong prognostic factors in patients with head and neck squamous cell carcinoma (HNSCC). STUDY
DESIGN: We examined expression levels of total and nuclear EGFR as well as p16 status based on evidence that nuclear EGFR may have a role in DNA damage repair.
METHODS: An HPV-negative (SQ20B) and an HPV-positive (UMSCC47) HNSCC cell line were examined for EGFR and γH2AX expression. A tissue microarray containing 123 cores obtained from 101 HNSCC tumors was analyzed for EGFR expression by automated quantitative analysis and p16 expression by immunohistochemical staining, and these results were correlated with available clinical data.
RESULTS: SQ20B had higher EGFR expression than UMSCC47. Nuclear localization of EGFR on activation with transforming growth factor-α was observed in SQ20B, but not in UMSCC47. SQ20B also had increased γH2AX foci compared to UMSCC47, suggesting that SQ20B has more DNA damage compared to UMSCC47. Total and nuclear EGFR was reliably obtained from 80 of 101 patients. p16 levels were determined in 87 of 101 patients. p16 levels were strongly associated with the oropharyngeal subsite and poorly differentiated histology. Expression of total and nuclear EGFR was higher in p16-negative tumors compared to p16-positive tumors (Wilcoxon rank test, P = .038 and P = .014, respectively).
CONCLUSIONS: Further studies are required to determine a mechanistic link between these two prognostic factors and the significance of EGFR localization to nucleus in DNA damage repair pathway activation.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23086695      PMCID: PMC3574977          DOI: 10.1002/lary.23647

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  31 in total

1.  Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis.

Authors:  Amanda Psyrri; Ziwei Yu; Paul M Weinberger; Clarence Sasaki; Bruce Haffty; Robert Camp; David Rimm; Barbara Ann Burtness
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.

Authors:  Lisa Licitra; Federica Perrone; Paolo Bossi; Simona Suardi; Luigi Mariani; Raffaella Artusi; Maria Oggionni; Chiara Rossini; Giulio Cantù; Massimo Squadrelli; Pasquale Quattrone; Laura D Locati; Cristiana Bergamini; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  J Clin Oncol       Date:  2006-12-20       Impact factor: 44.544

3.  EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.

Authors:  Gianmaria Liccardi; John A Hartley; Daniel Hochhauser
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

4.  Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase.

Authors:  Klaus Dittmann; Claus Mayer; Birgit Fehrenbacher; Martin Schaller; Uma Raju; Luka Milas; David J Chen; Rainer Kehlbach; H Peter Rodemann
Journal:  J Biol Chem       Date:  2005-07-05       Impact factor: 5.157

5.  Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.

Authors:  Hui-Wen Lo; Weiya Xia; Yongkun Wei; Mohamed Ali-Seyed; Shiu-Feng Huang; Mien-Chie Hung
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

6.  Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues.

Authors:  U Marti; C Ruchti; J Kämpf; G A Thomas; E D Williams; H J Peter; H Gerber; U Bürgi
Journal:  Thyroid       Date:  2001-02       Impact factor: 6.568

Review 7.  Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function.

Authors:  Klaus Dittmann; Claus Mayer; H Peter Rodemann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

8.  Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

9.  Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427.

Authors:  Khurram Khan; Koji Araki; Daiyou Wang; Guayan Li; Xin Li; Jie Zhang; Weizheng Xu; Randall K Hoover; Susan Lauter; Bert O'Malley; Rena G Lapidus; Daqing Li
Journal:  Head Neck       Date:  2010-03       Impact factor: 3.147

Review 10.  EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.

Authors:  Hui-Wen Lo
Journal:  Curr Mol Pharmacol       Date:  2010-01       Impact factor: 3.339

View more
  6 in total

1.  p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary.

Authors:  Lanea M Keller; Thomas J Galloway; Thomas Holdbrook; Karen Ruth; Donghua Yang; Cara Dubyk; Douglas Flieder; Miriam N Lango; Ranee Mehra; Barbara Burtness; John A Ridge
Journal:  Head Neck       Date:  2014-01-13       Impact factor: 3.147

Review 2.  Non-canonical signaling mode of the epidermal growth factor receptor family.

Authors:  Heng-Huan Lee; Ying-Nai Wang; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

Review 3.  Human Papillomavirus-Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials.

Authors:  Aarti Bhatia; Barbara Burtness
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

4.  Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.

Authors:  Guoqing Qian; Ning Jiang; Dongsheng Wang; Scott Newman; Sungjin Kim; Zhengjia Chen; Gabriela Garcia; Gavin MacBeath; Dong M Shin; Fadlo R Khuri; Zhuo G Chen; Nabil F Saba
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

5.  Crumbs 3b promotes tight junctions in an ezrin-dependent manner in mammalian cells.

Authors:  Andrew M Tilston-Lünel; Kathryn E Haley; Nicolas F Schlecht; Yanhua Wang; Abigail L D Chatterton; Susana Moleirinho; Ailsa Watson; Harinder S Hundal; Michael B Prystowsky; Frank J Gunn-Moore; Paul A Reynolds
Journal:  J Mol Cell Biol       Date:  2016-10-01       Impact factor: 6.216

Review 6.  Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?

Authors:  Stuart E Samuels; Avraham Eisbruch; Jonathan J Beitler; June Corry; Carol R Bradford; Nabil F Saba; Michiel W M van den Brekel; Robert Smee; Primož Strojan; Carlos Suárez; William M Mendenhall; Robert P Takes; Juan P Rodrigo; Missak Haigentz; Alexander D Rapidis; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-13       Impact factor: 3.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.